Axicabtagene ciloleucel
Term · Oncology and biomedicine · MLC-T-ONC-000866
A drug used to treat adults with follicular lymphoma or certain types of large B-cell lymphoma that relapsed (came back) or did not get better after treatment with at least two other types of systemic therapy. It is also being studied in the treatment of other types of cancer. Axicabtagene ciloleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Axicabtagene ciloleucel binds to a protein called CD19, which is found on most B-cell lymphoma cells. This helps the body’s immune system kill cancer cells. Axicabtagene ciloleucel is a type of CAR T-cell therapy. Also called Yescarta.
A preparation of autologous peripheral blood T lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.
| Identifier | MLC-T-ONC-000866 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Yescarta; KTE-C19 CAR |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-000866",
"term": "Axicabtagene ciloleucel",
"field": "Oncology and biomedicine",
"definitions": [
"A drug used to treat adults with follicular lymphoma or certain types of large B-cell lymphoma that relapsed (came back) or did not get better after treatment with at least two other types of systemic therapy. It is also being studied in the treatment of other types of cancer. Axicabtagene ciloleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Axicabtagene ciloleucel binds to a protein called CD19, which is found on most B-cell lymphoma cells. This helps the body’s immune system kill cancer cells. Axicabtagene ciloleucel is a type of CAR T-cell therapy. Also called Yescarta.",
"A preparation of autologous peripheral blood T lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development."
],
"synonyms": [
"Yescarta",
"KTE-C19 CAR"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/axicabtagene-ciloleucel/"
}
Record 3,186 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.